2024
Effectiveness of dolutegravir-based regimens compared to raltegravir-, elvitegravir-, bictegravir, and darunavir-based regimens among older adults with HIV in the Veterans Aging Cohort Study (VACS)
Yan L, Henegar C, Marconi V, Gordon K, Hicks C, Vannappagari V, Justice A, Aslan M. Effectiveness of dolutegravir-based regimens compared to raltegravir-, elvitegravir-, bictegravir, and darunavir-based regimens among older adults with HIV in the Veterans Aging Cohort Study (VACS). AIDS Research And Therapy 2024, 21: 96. PMID: 39709467, PMCID: PMC11662819, DOI: 10.1186/s12981-024-00681-w.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmidesAnti-HIV AgentsCohort StudiesDarunavirDrug Therapy, CombinationFemaleHeterocyclic Compounds, 3-RingHeterocyclic Compounds, 4 or More RingsHIV InfectionsHIV Integrase InhibitorsHumansMaleMiddle AgedOxazinesPiperazinesPyridazinesPyridonesQuinolonesRaltegravir PotassiumTreatment OutcomeVeteransViral LoadConceptsVeterans Aging Cohort StudyRAL-based regimenAntiretroviral therapyAging Cohort StudyCohort studyOdds of virologic suppressionIntegrase strand transfer inhibitorsDarunavir-based regimensDolutegravir-based regimensDTG-based regimensAntiretroviral therapy experienceHuman immunodeficiency virusDTG-based regimenInverse probability of treatment weightingStrand transfer inhibitorsBackgroundReal-world dataProbability of treatment weightingMethodsThis cohort studyVirologic suppressionVirological failureVirological effectImmunodeficiency virusDarunavir/ritonavirClinical outcomesRegimen initiationCorrelates of Risk for Disinhibited Behaviors in the Million Veteran Program Cohort
Barr P, Bigdeli T, Meyers J, Peterson R, Sanchez-Roige S, Mallard T, Dick D, Harden K, Wilkinson A, Graham D, Nielsen D, Swann A, Lipsky R, Kosten T, Aslan M, Harvey P, Kimbrel N, Beckham J, Aslan M, Antonelli M, de Asis M, Bauer M, Brophy M, Concato J, Cunningham F, Freedman R, Gaziano M, Gleason T, Harvey P, Huang G, Kelsoe J, Kosten T, Lehner T, Lohr J, Marder S, Miller P, O Leary T, Patterson T, Peduzzi P, Przygodski R, Siever L, Sklar P, Strakowski S, Zhao H, Fanous A, Farwell W, Malhorta A, Mane S, Palacios P, Bigdeli T, Corsey M, Zaluda L, Johnson J, Sueiro M, Cavaliere D, Jeanpaul V, Maffucci A, Mancini L, Deen J, Muldoon G, Whitbourne S, Canive J, Adamson L, Calais L, Fuldauer G, Kushner R, Toney G, Lackey M, Mank A, Mahdavi N, Villarreal G, Muly E, Amin F, Dent M, Wold J, Fischer B, Elliott A, Felix C, Gill G, Parker P, Logan C, McAlpine J, DeLisi L, Reece S, Hammer M, Agbor-Tabie D, Goodson W, Aslam M, Grainger M, Richtand N, Rybalsky A, Al Jurdi R, Boeckman E, Natividad T, Smith D, Stewart M, Torres S, Zhao Z, Mayeda A, Green A, Hofstetter J, Ngombu S, Scott M, Strasburger A, Sumner J, Paschall G, Mucciarelli J, Owen R, Theus S, Tompkins D, Potkin S, Reist C, Novin M, Khalaghizadeh S, Douyon R, Kumar N, Martinez B, Sponheim S, Bender T, Lucas H, Lyon A, Marggraf M, Sorensen L, Surerus C, Sison C, Amato J, Johnson D, Pagan-Howard N, Adler L, Alerpin S, Leon T, Mattocks K, Araeva N, Sullivan J, Suppes T, Bratcher K, Drag L, Fischer E, Fujitani L, Gill S, Grimm D, Hoblyn J, Nguyen T, Nikolaev E, Shere L, Relova R, Vicencio A, Yip M, Hurford I, Acheampong S, Carfagno G, Haas G, Appelt C, Brown E, Chakraborty B, Kelly E, Klima G, Steinhauer S, Hurley R, Belle R, Eknoyan D, Johnson K, Lamotte J, Granholm E, Bradshaw K, Holden J, Jones R, Le T, Molina I, Peyton M, Ruiz I, Sally L, Tapp A, Devroy S, Jain V, Kilzieh N, Maus L, Miller K, Pope H, Wood A, Meyer E, Givens P, Hicks P, Justice S, McNair K, Pena J, Tharp D, Davis L, Ban M, Cheatum L, Darr P, Grayson W, Munford J, Whitfield B, Wilson E, Melnikoff S, Schwartz B, Tureson M, D Souza D, Forselius K, Ranganathan M, Rispoli L, Sather M, Colling C, Haakenson C, Kruegar D, Muralidhar S, Ramoni R, Breeling J, Chang K, O Donnell C, Tsao P, Moser J, Brewer J, Warren S, Argyres D, Stevens B, Humphries D, Do N, Shayan S, Nguyen X, Pyarajan S, Cho K, Hauser E, Sun Y, Wilson P, McArdle R, Dellitalia L, Harley J, Whittle J. Correlates of Risk for Disinhibited Behaviors in the Million Veteran Program Cohort. JAMA Psychiatry 2024, 81: 188-197. PMID: 37938835, PMCID: PMC10633411, DOI: 10.1001/jamapsychiatry.2023.4141.Peer-Reviewed Original ResearchSubstance use disordersPolygenic risk scoresMillion Veteran ProgramCorrelates of riskElectronic health recordsPsychiatric problemsComorbid psychiatric problemsViral hepatitis C.Chronic airway obstructionHealth recordsElectronic health record dataUS veteran populationMillion Veteran Program cohortCommon etiologic pathwayHealth care centersHealth record dataInternational Statistical ClassificationSuicide-related behaviorsAirway obstructionCohort studyHepatitis C.Recent genome-wide association studiesLiver diseaseUS veteransCare center
2023
Metformin prescription for U.S. veterans with prediabetes, 2010–2019
Gulanski B, Goulet J, Radhakrishnan K, Ko J, Li Y, Rajeevan N, Lee K, Heberer K, Lynch J, Streja E, Mutalik P, Cheung K, Concato J, Shih M, Lee J, Aslan M. Metformin prescription for U.S. veterans with prediabetes, 2010–2019. Journal Of Investigative Medicine 2023, 72: 139-150. PMID: 37668313, DOI: 10.1177/10815589231201141.Peer-Reviewed Original ResearchConceptsBody mass indexVeterans Health AdministrationIncident prediabetesHigh riskHealth AdministrationRetrospective observational cohort studyType 2 diabetes mellitusUse of metforminObservational cohort studyProportion of veteransMetformin prescribingGestational diabetesCohort studyMetformin prescriptionDiabetes mellitusDiabetes preventionMass indexCardiovascular diseaseMultivariable modelPrediabetesSubset of individualsMetforminU.S. veteransHealthcare systemVeteransAnti–SARS-CoV-2 Pharmacotherapies Among Nonhospitalized US Veterans, January 2022 to January 2023
Yan L, Streja E, Li Y, Rajeevan N, Rowneki M, Berry K, Hynes D, Cunningham F, Huang G, Aslan M, Ioannou G, Bajema K. Anti–SARS-CoV-2 Pharmacotherapies Among Nonhospitalized US Veterans, January 2022 to January 2023. JAMA Network Open 2023, 6: e2331249. PMID: 37651140, PMCID: PMC10472184, DOI: 10.1001/jamanetworkopen.2023.31249.Peer-Reviewed Original ResearchConceptsCOVID-19 pharmacotherapyVeterans Health AdministrationVeterans Integrated Service NetworkSARS-CoV-2Higher Charlson Comorbidity Index scoresCharlson Comorbidity Index scoreNon-Hispanic veteransComorbidity Index scoreProportion of patientsSymptomatic COVID-19Multivariable logistic regressionCOVID-19 vaccinationCohort studyMedicare databaseVHA careUS veteransMAIN OUTCOMEMedical conditionsHispanic veteransPharmacotherapyHealth AdministrationIndex scoreCommunity careNonhospitalized personsWhite veterans
2022
1265. Effectiveness and Durability of Dolutegravir (DTG)-Based Regimens in Older People Living with HIV (PLWH) from the Veterans Aging Cohort Study (VACS)
Yan L, Henegar C, Gordon K, Hicks C, Vannappagari V, Justice A, Aslan M. 1265. Effectiveness and Durability of Dolutegravir (DTG)-Based Regimens in Older People Living with HIV (PLWH) from the Veterans Aging Cohort Study (VACS). Open Forum Infectious Diseases 2022, 9: ofac492.1096. PMCID: PMC9752102, DOI: 10.1093/ofid/ofac492.1096.Peer-Reviewed Original ResearchVeterans Aging Cohort StudyDTG-based regimensAging Cohort StudyViiV HealthcareCohort studyOlder peopleART-experienced individualsCD4 cell countEnd of studyRegimen discontinuationRegimen initiationAntiretroviral regimensVirologic failureART-naïveMultiple comorbiditiesHIV managementOlder PLWHPLWHTreatment responseTreatment statusRegimensTreatment experienceDolutegravirRaltegravirCell countEarly Adoption of Anti–SARS-CoV-2 Pharmacotherapies Among US Veterans With Mild to Moderate COVID-19, January and February 2022
Bajema K, Wang X, Hynes D, Rowneki M, Hickok A, Cunningham F, Bohnert A, Boyko E, Iwashyna T, Maciejewski M, Viglianti E, Streja E, Yan L, Aslan M, Huang G, Ioannou G. Early Adoption of Anti–SARS-CoV-2 Pharmacotherapies Among US Veterans With Mild to Moderate COVID-19, January and February 2022. JAMA Network Open 2022, 5: e2241434. PMID: 36367727, PMCID: PMC9652752, DOI: 10.1001/jamanetworkopen.2022.41434.Peer-Reviewed Original ResearchConceptsCOVID-19 pharmacotherapySevere COVID-19SARS-CoV-2Health care systemCohort studyRisk factorsCare systemMedical conditionsCOVID-19Positive SARS-CoV-2 testVeterans Affairs Health Care SystemCOVID-19-related hospitalizationCOVID-19-related symptomsLarge integrated health care systemSARS-CoV-2 testVA health care systemIntegrated health care systemNon-Hispanic veteransModerate COVID-19Odds of receiptMultivariable logistic regressionCOVID-19 vaccinationMedical comorbiditiesMedian ageAnti-SARS
2013
Design of “Neuropsychological and Mental Health Outcomes of Operation Iraqi Freedom: A Longitudinal Cohort Study”
Aslan M, Concato J, Peduzzi P, Proctor S, Schnurr P, Marx B, McFall M, Gleason T, Huang G, Vasterling J. Design of “Neuropsychological and Mental Health Outcomes of Operation Iraqi Freedom: A Longitudinal Cohort Study”. Journal Of Investigative Medicine 2013, 61: 569. DOI: 10.231/jim.0b013e31828407ff.Peer-Reviewed Original ResearchNeurocognition Deployment Health StudyPosttraumatic stress disorderOperation Iraqi FreedomStudy designVA Cooperative Studies ProgramSubsequent posttraumatic stress disorderLongitudinal cohort studyStatistical analysis planTraumatic brain injuryMental health disordersTarget sample sizeCooperative Studies ProgramIraqi FreedomTiming of assessmentMental health outcomesCurrent study dataUS Army soldiersCohort studyBrain injuryStudy populationHealth StudyPostdeployment assessmentsHealth disordersNeuropsychological changesHealth outcomes